{"name":"Biocon Biologics Inc.","slug":"biocon-biologics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Bmab1200","genericName":"Bmab1200","slug":"bmab1200","indication":"Other","status":"phase_3"},{"name":"Bmab 1000","genericName":"Bmab 1000","slug":"bmab-1000","indication":"Other","status":"phase_3"},{"name":"JOBEVNE","genericName":"BEVACIZUMAB-NWGD","slug":"bevacizumab-nwgd","indication":"Other","status":"marketed"},{"name":"YESAFILI","genericName":"AFLIBERCEPT-JBVF","slug":"aflibercept-jbvf","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Stelara","genericName":"Stelara","slug":"stelara","indication":"Crohn's disease","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Herceptin Hylecta®","genericName":"Herceptin Hylecta®","slug":"herceptin-hylecta","indication":"HER2-positive early breast cancer (adjuvant and neoadjuvant treatment)","status":"marketed"}]}],"pipeline":[{"name":"Stelara","genericName":"Stelara","slug":"stelara","phase":"marketed","mechanism":"Stelara binds to the p40 subunit of IL-12 and IL-23, reducing inflammation in autoimmune diseases.","indications":["Crohn's disease","Plaque psoriasis","Psoriasis","Psoriasis with arthropathy","Ulcerative colitis"],"catalyst":""},{"name":"Bmab1200","genericName":"Bmab1200","slug":"bmab1200","phase":"phase_3","mechanism":"Bmab1200 is a monoclonal antibody targeting a specific immune or disease-related antigen to modulate immune response or block pathogenic signaling.","indications":[],"catalyst":""},{"name":"Bmab 1000","genericName":"Bmab 1000","slug":"bmab-1000","phase":"phase_3","mechanism":"Bmab 1000 is a monoclonal antibody targeting a specific molecular pathway, though the exact target is not publicly disclosed in available sources.","indications":[],"catalyst":""},{"name":"Herceptin Hylecta®","genericName":"Herceptin Hylecta®","slug":"herceptin-hylecta","phase":"marketed","mechanism":"Herceptin Hylecta is a subcutaneous formulation of trastuzumab that binds to HER2 receptors on cancer cells to block growth signaling and trigger immune-mediated cell death.","indications":["HER2-positive early breast cancer (adjuvant and neoadjuvant treatment)","HER2-positive metastatic breast cancer","HER2-positive gastric or gastroesophageal junction adenocarcinoma"],"catalyst":""},{"name":"JOBEVNE","genericName":"BEVACIZUMAB-NWGD","slug":"bevacizumab-nwgd","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"YESAFILI","genericName":"AFLIBERCEPT-JBVF","slug":"aflibercept-jbvf","phase":"marketed","mechanism":"","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-01-15","type":"pipeline","source":"ET Now","summary":"Biocon QIP: Pharma major raises Rs 4150 crore to fund Biologics integration - ET Now","headline":"Biocon QIP: Pharma major raises Rs 4150 crore to fund Biologics integration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQVzZLY2tjdzROUXFXT1pSd3FEdm1sV2lhcTFDdHl5MkV1NU1BVW92aTBlbHB6MTR3V2gwX3ljLWtkYXlHeFJDcC1zb3dDT0lGWFNfcE4zbng3WVdzZW9VZ1FpSk96dmxQSGpUOERBUVVQVlo4bS1RcW15dEF1YndqTWROTGtPbkxVOEFTbExRUGJUaTRJeU9PLUZMZVFxUTRoNTZYUnBid0g2aVFBU2FBSWtLWXlsOE0wb1M2QjdGQ0tvOFNBbkwyOGFoeXdfeHg2cjJIMkh1dUZxUQ?oc=5","date":"2025-12-23","type":"regulatory","source":"scanx.trade","summary":"Biocon Partners With Ajanta Pharma to Market Semaglutide Across 26 International Markets - scanx.trade","headline":"Biocon Partners With Ajanta Pharma to Market Semaglutide Across 26 International Markets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxQUF9EU3JSSG1aa2tuWWFSZkprZXNVRHE1anNYSmg1eU1oalo5Q0tsd2JYR1JmT25FUEtpOV9MaEZyb3llWWpSLUFJX1VRZGpxczFqVllrcDBPUndWdzJuVWxDaDZqMzNMME5tc2V4SEp1RmdaRzBoUHBSSF9zdGQ3Q0FlNkpYTk11NXQ4MWJSbE5fMVdOWEt3RlMwV0dMMUFscktDMklaQmZCeGg4SzRXdGx2R1pSVjdvVm12YjVjZnptRHdyejdHRDhWcFU0NjEzTkl2RmVnM3lEQlVYODhQbjk5M0o2bE9qVm9CQkV3ZDBFSXF4SGhPUNIB_gFBVV95cUxPN0ozWXpwUE1vMnV5UU1xNVZsWGpvVjJySWFRc3R4S3duRk1pUFQ3QnpuSk1fV3hGWEYtcHBzakNnTm5JSERkcDFoWjJiYVdYN2hWSEJJQUtMUnhHbXgxMkRKd0NjR2duMGk2ODVpVktNM2xYMWJjZDdEa2xpS0RsX01RbGlHUVl0eVhOR3lpWkMxMWlZZWNQYm93ckc2bG4zU0pvcDY5dDZlM0xZUVFXV1B2SWxYeGxQX0p3Vm9FYWptTHFJbTh4LWZ1QXU1NXl1b2hUa0xSV1JwVThlcmg2c0UwS0V1bW94dnVYcXJKQjNxV0ZsbXdrRGxYZ0UwUQ?oc=5","date":"2025-12-06","type":"deal","source":"ET Pharma","summary":"Biocon to merge Biocon Biologics with itself; to acquire stake held by Serum, Mylan - ET Pharma","headline":"Biocon to merge Biocon Biologics with itself; to acquire stake held by Serum, Mylan","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-06","type":"deal","source":"Mint","summary":"Biocon to merge biologics unit in $5.5 billion deal - Mint","headline":"Biocon to merge biologics unit in $5.5 billion deal","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-02","type":"patent","source":"Express Pharma","summary":"Biocon Biologics reaches settlement with Amgen for Denosumab biosimilars commercialisation - Express Pharma","headline":"Biocon Biologics reaches settlement with Amgen for Denosumab biosimilars commercialisation","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-17","type":"regulatory","source":"medicaldialogues.in","summary":"Biocon Biologics, Civica expand partnership, launch private label Insulin Glargine to broaden US... - medicaldialogues.in","headline":"Biocon Biologics, Civica expand partnership, launch private label Insulin Glargine to broaden US...","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-17","type":"deal","source":"Express Pharma","summary":"Biocon Biologics expands partnership with Civica to launch Insulin Glargine in the US - Express Pharma","headline":"Biocon Biologics expands partnership with Civica to launch Insulin Glargine in the US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOUlF2ZmZZTmVsUjJxWW1Qbjl1OFpvMTNmTzQxaG81X01aUzJGcENobDZLNG5ZUGw5dmtrSVlHdWdvMmZ0T0ZlM2pXU2FlX21aYUkxY19oeS1ydlc4MHVSbjBraVZpaWhNZi11MUw1ZUl3MU1tcGRacVkwSEZwdlMxaEdSb2s1WDkzVzdNUW5waFhuMUY1NERnVloxZktBTWdGa2UyYWpVQXBjMnhtNVM2NE5uQS15Yl9ieWVHbHgtTHM3MWd6VTZYTlctT3d3bF9uci1ONjFRNGIxZWVhem9UVFJzZkJoNTdiUmljMndkX2p2eGE3N2lPbHZST2xsN0E?oc=5","date":"2025-10-16","type":"regulatory","source":"BioSpace","summary":"Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options - BioSpace","headline":"Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatm","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-07","type":"regulatory","source":"Business Standard","summary":"Biocon gets USFDA's tentative approval for antibacterial drug Rifaximin - Business Standard","headline":"Biocon gets USFDA's tentative approval for antibacterial drug Rifaximin","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQM0tPOTR6RkhRems1VGJDSHREWGwwVWJWdnBzNGMxSkJpaGI4Rmc2V0oyVlZVd21lUFZnYVVlNzFoZkZoTGpPYUI2TlF3aDZkYVlTY3JIenpyOTE2aDNKSHlTeGEzNzdBSllsRjRlbTI0YkRMeHh2bXdwUXRhbkFDYm50TUdxSl92N29B?oc=5","date":"2025-09-15","type":"pipeline","source":"Yahoo Finance","summary":"Samsung Biologics, Amgen and Biocon invest in US pharma sites - Yahoo Finance","headline":"Samsung Biologics, Amgen and Biocon invest in US pharma sites","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-05","type":"pipeline","source":"The Economic Times","summary":"Biocon Biologics secures multiple market access agreements in US for Yesintek - The Economic Times","headline":"Biocon Biologics secures multiple market access agreements in US for Yesintek","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNeVFmRjZpczFvYk5IZEg2dUJnNjFDV2JlcXhQOTloM2ktQWtVdnZQeG91QWd4bTEtVFpjRlh2ZUwzWlVDaDdIYkh2WVh3ZE9xQU9TeDQ0ZkgxM1I3UGg0R3lJWmFNRktFVU9BeHlfczRSczFuYTZTMmU1blIwdFNhejB6R1VFWTFZUDJncFB3WTdiRHp6YU9CY1I1cHl0T1RFZEFsWWxqXy1aQlJ2Und2dWlLaXZnOGxaUE0yWjJkWWtZVjRtN0Y0OG9zMmdoM2o1aGJtbzlUZmc1SWdQX1NnaS1ORy1CeVU?oc=5","date":"2025-03-06","type":"pipeline","source":"PR Newswire","summary":"Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States - PR Newswire","headline":"Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"marketed":4,"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}